DiaMedica CMO Lorianne Masuoka resigns; Julie Krop appointed as successor

DiaMedica Therapeutics Inc.

Lorianne Masuoka resigned as CMO effective Aug 4, 2025 for personal reasons; separation agreement provides health benefits through Oct 2026.
Julie Krop appointed as CMO effective Aug 11, 2025; Krop brings 20+ years experience, most recently CMO at PureTech Health.
Krop previously CMO at Freeline Therapeutics and AMAG Pharmaceuticals; involved in preeclampsia drug development at AMAG.
Krop will lead clinical development of DM199 for preeclampsia and acute ischemic stroke.

item 5.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.